Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
Innovate UK Grant Awarded for MultiStem(R) Therapy Clinical Trial in United Kingdom
LONDON and CLEVELAND, Jan. 22, 2015 (GLOBE NEWSWIRE) — Athersys Limited (an affiliate of Athersys, Inc.) (Nasdaq:ATHX) and the Cell Therapy Catapult, a not-for-profit centre, which is focused on the development of the United Kingdom cell therapy industry to increase the nation’s health and wealth, are pleased to announce that Athersys Limited has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, which will support a Phase 2a clinical study evaluating the administration of MultiStem® cell therapy to acute respiratory distress syndrome (ARDS) patients.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.